August 29, 2016
(USA Today) – Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor’s 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan’s, according to a USA TODAY analysis of data from S&P Global Market Intelligence.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.